Insider Buying Week 06-27-25

Never a dull moment in the Trump show.  Insiders like most investors are on the sidelines watching the show.

Name: Peter Busch Orthwein 
Position: Director
Transaction Date: 06-20-2025 Shares Bought: 3,000 shares an Average Price Paid of $85.40 for Cost: $256,200

Company: Thor Industries Inc. (THO):

Thor Industries, Inc., founded in 1980, is the world’s largest manufacturer of recreational vehicles and a leading player in both North America and Europe. The company produces a broad range of RVs in the United States and Europe and distributes them—along with related parts and accessories—primarily through independent, non-franchise dealers across the United States, Canada, and Europe. Thor Industries is incorporated in Delaware and is headquartered in Elkhart, Indiana.

Peter Busch-Orthwein, co-founder of Thor Industries in August 1980, has served as a Director and member of the Board since the company’s inception. His leadership roles have included Chairman, Vice Chairman and Treasurer, Chief Executive Officer and Chairman, and Executive Chairman until 2019. He currently holds the title of Chairman Emeritus. Mr. Busch-Orthwein is a graduate of Choate Rosemary Hall and earned a Bachelor of Science in Applied Economics from Cornell University in 1968, followed by an MBA from Cornell in 1969.

Opinion:

Name: Mark Okey Decker Jr
Position: CEO and President
Transaction Date: 06-24-2025  Shares Bought: 160,000 shares an Average Price Paid of $6.52 for Cost: $1,042,528

Company: Global Medical REIT Inc. (GMRE):

Global Medical REIT Inc. is a Maryland-based, internally managed real estate investment trust that acquires and leases healthcare facilities to physician groups and regional or national healthcare providers. The company is listed on the New York Stock Exchange and has elected to be taxed as a REIT for U.S. federal income tax purposes, effective for the tax year ending December 31, 2016. Its operations are conducted through Global Medical REIT L.P., a Delaware limited partnership, with Global Medical REIT GP LLC serving as its sole general partner.

Mark Okey Decker Jr. was appointed Chief Executive Officer and President of Global Medical REIT Inc. on June 23, 2025, and concurrently joined the company’s Board of Directors. Prior to joining GMRE, he co-founded and led the net lease real estate investing strategy at Proterra Investing Partners. He previously served as President, Chief Executive Officer, Trustee, and Chief Investment Officer at Centerspace, and held senior investment banking roles at BMO Capital Markets. Mr. Decker holds a Bachelor of Arts in History from the College of William and Mary.

Opinion:

Name: Clint D. Coghill
Position: Director
Transaction Date: 06-20-2025 Shares Bought: 150,000 shares an Average Price Paid of $3.67 for Cost: $550,500

Company: Amplify Energy Corp. (AMPY):

Amplify Energy is an independent oil and gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties. Given the similar economic characteristics of its operations, the company operates as a single reportable segment. Activities are conducted through wholly owned subsidiaries, with assets primarily consisting of producing properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas, North Louisiana, and the Eagle Ford region. Most of these assets are situated within large, mature oil and gas reservoirs.

Clint D. Coghill joined the Board of Directors of Amplify Energy Corp. as Lead Independent Director on May 16, 2025. He brings over 30 years of experience in finance and technology, having founded Backstop Solutions Group and previously serving as President and Chief Investment Officer at Coghill Capital Management. Mr. Coghill holds a Bachelor of Arts in Business Administration from the University of Arizona and an MBA from the London Business School.

Opinion:

Name: Gravitas Capital LP
Position: Executive Chairman, 10% Owner
Transaction Date: 06-20-2025 Shares Bought: 337,838 shares an Average Price Paid of $1.48 for Cost: $500,000

Company: Tharimmune Inc. (THAR):

Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates for rare, inflammatory, and oncologic diseases with significant unmet medical needs in the United States. Its preclinical immuno-oncology pipeline includes TH104, a candidate targeting liver-related and other pruritogenic inflammatory conditions; TH023, currently in Phase 1 clinical trials for multiple high-value autoimmune indications; and HS1940, which targets programmed cell death protein 1. The company has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Formerly known as Hillstream BioPharma, Inc., the company changed its name to Tharimmune, Inc. in September 2023. It was founded in 2017 and is headquartered in Bridgewater, New Jersey.

Opinion:

---

This blog is solely for educational purposes and the author’s own amusement. IT IS NOT INVESTMENT ADVICE.  Think of the blog as part of my personal investment journal that I am willing to share with the DIY investor. There are also many parts that I am not willing to share if I think it could influence trading action or be detrimental to the Fund’s partners. We could be long, short, or have no position at all in any of the stocks mentioned and express no written or implied obligation to disclose any of that.  Nothing contained here constitutes a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal, and past performance is not indicative of future results.

“The insomniac hedge fund guy” is a moniker Harvey Sax, the portfolio manager for The Insiders Fund” has used from time to time on email, blog ,and social media posts. While Mr. Sax is the portfolio manager of The Insiders Fund, these posts are not communications from, nor endorsed by, Alpha Wealth Funds, LLC or any of its managed funds. References to Alpha Wealth Funds or its affiliates are for identification only and do not imply sponsorship or approval.

The Insiders Fund and its blogs and posts are not affiliated with, endorsed by, or sponsored by any of the companies mentioned herein. All company names, logos, and trademarks belong to their respective owners. The use of company logos is solely for descriptive and illustrative purposes under fair use.  Any information provided is based on publicly available data and should not be considered financial, investment, or legal advice. Readers should conduct their own research or consult with a professional before making any investment decisions. Insiders sell the stock for many reasons, but they generally buy for just one – to make money. You’ve always heard the best information is inside information.  Everyone with any stock market experience pays close attention to what insiders are doing.  After all, who knows a business better than the people running it?  Officers, directors, and 10% owners are required to inform the public through a Form 4 Filing of any transaction, buy, sell, exercise, or any other within 48 hours of doing so.

This info is available for free from the SEC’s Web site, Edgar, although we subscribe to SECForm4  as they provide a way to manage and make sense of the vast realms of data. I’ve tried a lot of vendors. SECForm4 is one of the smaller ones, but I like supporting Frank. He is not arrogant. He’s helpful and has great prices. He also trades on his own data, so I like people that eat what they kill. The bar is different from selling because the natural state of management is to be a seller. This is because most companies provide significant amounts of management compensation packages as stock and options. Therefore, we analyze unusual patterns with selling, such as insiders selling 25 percent or more of their holdings or multiple insiders selling near 52-week lows. Another red flag is large planned sale programs that start without warning. Unfortunately, the public information disclosure requirements about these programs, referred to as Rule 10b5-1, are horrendously poor. Also, planned sales that pop up out of nowhere are basically sales and are seeking cover under this corporate welfare loophole.

I also generally ignore 10 percent shareholders as they tend to be OPM (other people’s money) and perhaps not the smart money on which we are trying to read the tea leaves. I say generally because some 10% shareholders are great investor, think Warren  Buffett and others.  Of course, insiders can also be wrong about their Company’s prospects. Don’t let anyone fool you into believing they never make mistakes.  Do your own analysis. They can easily be wrong, and in many cases, maybe most cases, have no more idea what the future may hold than you or me. In short, you can lose money following them.  We have, and we curse aloud; what were they thinking!We like Fly on the Wall for keeping up with what events might be happening, analysts’ comments, and whatever else could be moving the stock.  Dow Jones news service is an essential tool, but many services pick up their feed like they do Bloomberg. She probes the 10k for a reasonable description of the business. I’ve found that to be the most accurate and succinct place to find out what a business actually does. When I have time, over the weekend, I’ll add some preliminary analysis to the Opinion at the end. It is largely done now by my AI. Sometimes I won’t update this for a couple of weeks or more.  A good way to use this blog is as I do, it’s a reference point and filing cabinet for various stocks with notable insider buying. It’s one of many tools I use.